nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. Genetic abnormalities and aberrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results